New methods for diagnosing and treating type 2 diabetes nephropathy
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
This study is testing new ways to diagnose and treat kidney problems in people with type 2 diabetes by using advanced tools and combining different medical approaches.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05888909 on ClinicalTrials.gov |
What this trial studies
This study focuses on the serious complications of diabetic nephropathy in patients with type 2 diabetes. It aims to establish a long-term follow-up system that utilizes sensitive biomarkers, imaging techniques, and digital markers to comprehensively assess the progression of the disease. By developing a multimodal non-invasive diagnostic model and a new clinical staging system, the research seeks to create an accurate diagnosis and treatment framework that integrates both traditional Chinese and Western medicine approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of type 2 diabetes and a complete medical history.
Not a fit: Patients with hereditary kidney diseases, urinary tract infections, autoimmune diseases, or those with a malignant tumor expected to survive less than 6 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and improved treatment options for patients with type 2 diabetes nephropathy.
How similar studies have performed: While there have been studies on diabetic nephropathy, this approach combining multiple diagnostic methods and traditional medicine is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age ≥ 18 years old, regardless of gender; Type 2 diabetes; Having a complete medical history and clinical data; If the patients with type 2 diabetes combined with CKD underwent renal biopsy, the pathological diagnosis should be clear; Patients voluntarily signs an informed consent form. Exclusion criteria: Incomplete medical history or clinical data; Patients with hereditary kidney disease; Combined urinary tract infection; Merge autoimmune system diseases; Patients with malignant tumor were expected to survive less than 6 months; Pregnancy and lactation.
Where this trial is running
Beijing
- Chinese PLA General Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Zheyi Dong, MD
- Email: shengdai26@163.com
- Phone: +86 010 66935462
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.